Drug intelligence / Profile preview

DTX-HSA-FA

Development stage
Preclinical
Lead developer
Tehran University of Medical Sciences
Modality
Small Molecules, Nanoparticles → Drug Delivery Systems
Administration
Intravenous
01

Overview

DTX-HSA-FA is a folate-targeted nanoparticle formulation of docetaxel conjugated to human serum albumin (HSA) and decorated with folic acid (FA). Developed by researchers at the Tehran University of Medical Sciences, the conjugate is designed to improve the water solubility of docetaxel and actively target cancer cells that overexpress folate receptors. By utilizing folic acid as a targeting ligand, the nanoparticles are selectively internalized by folate receptor-positive cancer cells, enhancing cytotoxicity and reducing systemic side effects. Preclinical in vitro and in vivo studies have demonstrated superior tumor reduction and survival rates compared to free docetaxel in breast cancer models.

Other names
docetaxel-human serum albumin-folic acid conjugatedocetaxel-human serum albumin-folic acid nanoparticlesfolate-decorated human serum albumin nanoparticles of docetaxelfolic acid-human serum albumin-docetaxel conjugate
02

Targets

FOLR1 (FRα)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on DTX-HSA-FA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DTX-HSA-FA.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call